Skip to main content

Table 1 Correlation between CLK1 expression and clinicopathological characteristics of PDAC patients

From: CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer

  Internal cohort (n = 186) External cohort (n = 158)
   High CLK1
n = 112
Low CLK1
n = 74
χ2 p   High CLK1
n = 96
Low CLK1
n = 62
χ2 p
Age           
 < 60 90 50 40 1.58 0.29 94 56 38 0.14 0.42
 > 60 96 62 34    64 40 24   
Gender           
 Male 99 61 38 0.17 0.68 85 52 33 0.013 0.91
 Female 87 51 36    73 44 29   
BMI           
 ≥ 28 53 33 20 0.13 0.72 62 36 26 0.31 0.58
 < 28 133 79 54    96 60 36   
Smoke           
 Yes 64 40 24 0.21 0.65 86 56 30 1.50 0.22
 No 122 72 50    72 40 32   
Differentiation           
 Low 91 49 42 3.02 0.08 77 48 29 0.16 0.69
 High/middle 95 63 32    81 48 33   
Lymphatic metastasis           
 Yes 126 85 45 4.817 0.028 88 59 26 5.776 0.016
 No 60 27 29    70 37 36   
Tumor size           
 > 4 cm 71 46 19 4.646 0.031 50 40 11 9.864 0.002
 ≤ 4 cm 115 66 55    108 56 51   
Microvascular invasion           
 Yes 60 42 18 3.54 0.06 64 37 27 0.39 0.53
 No 126 70 56    94 59 35   
ki-67           
 ≥ 20 74 48 26 1.11 0.29 69 43 26 0.13 0.72
 < 20 112 64 48    89 53 36   
TNM stage           
 II 116 61 55 7.49 0.006 96 53 45 4.83 0.028
 III 70 51 19    62 43 17   
  1. *P < 0.05 was considered significant